AI Article Synopsis

  • The article with DOI: 10.1371/journal.pone.0222259 has been corrected to address previous inaccuracies.
  • The corrections may involve updated data, revised conclusions, or clarifications to improve the article's overall integrity.
  • Readers should refer to the updated version for the most accurate information regarding the study.

Article Abstract

[This corrects the article DOI: 10.1371/journal.pone.0222259.].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211152PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253671PLOS

Publication Analysis

Top Keywords

correction biomarkers survival
4
survival patients
4
patients advanced
4
advanced hepatocellular
4
hepatocellular carcinoma
4
carcinoma treated
4
treated tgf-βri
4
tgf-βri inhibitor
4
inhibitor galunisertib
4
galunisertib [this
4

Similar Publications

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF

This study investigates the prognostic value of serum biomarkers PD-L1 and IGFBP-2 in patients with esophageal carcinoma. It finds a significant positive correlation between these biomarkers and established tumor markers CEA and CYFRA21-1. The 3-year survival rate for the patient cohort was 45.

View Article and Find Full Text PDF

Background: Lung cancer has high morbidity and mortality rates, which results in a poor prognosis. Cuproptosis is a novel cell death mechanism. The aim of this study was to examine the biological characteristics and clinical significance of genes associated with cuproptosis in lung adenocarcinoma (LUAD), and to understand the molecular mechanisms underlying the occurrence and progression of LUAD.

View Article and Find Full Text PDF

Comprehensive analysis pinpoints CCNA2 as a prognostic and immunological biomarker in non-small cell lung cancer.

BMC Pulm Med

January 2025

Medical Research Center, Affiliated Hospital of Jining Medical University, Jining Medical University, 89 Guhuai Road, Jining, Shandong Province, 272029, PR China.

Background: Lung cancer is a leading cause of morbidity and mortality globally. Despite advances in targeted and immunotherapies, overall survival (OS) rates remain suboptimal. Cyclin-A2 (CCNA2), known for its upregulation in various tumors and role in tumorigenesis, has an undefined function in non-small cell lung cancer (NSCLC).

View Article and Find Full Text PDF

The connection between metabolic reprogramming and tumor progression has been demonstrated in an increasing number of researches. However, further research is required to identify how metabolic reprogramming affects interpatient heterogeneity and prognosis in clear cell renal cell carcinoma (ccRCC). In this work, single-cell RNA sequencing (scRNA-seq) based deconvolution was utilized to create a malignant cell hierarchy with metabolic differences and to investigate the relationship between metabolic biomarkers and prognosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!